Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 560

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Open access
Tumeh, Paul C., Hellmann, Matthew D., Hamid, Omid, Tsai, Katy K., Loo, Kimberly L., Gubens, Matthew A., Rosenblum, Michael, Harview, Christina L., Taube, Janis M., Handley, Nathan, Khurana, Neharika, Nosrati, Adi, Krummel, Matthew F., Tucker, Andrew, Sosa, Eduardo V., Sanchez, Phillip J., Banayan, Nooriel, Osorio, Juan C., Nguyen-Kim, Dan L., Chang, Jeremy, Shintaku, I. Peter, Boasberg, Peter D., Taylor, Emma J., Munster, Pamela N., Algazi, Alain P., Chmielowski, Bartosz, Dummer, Reinhard, Grogan, Tristan R., Elashoff, David, Hwang, Jimmy, Goldinger, Simone M., Garon, Edward B., Pierce, Robert H., Daud, Adil·2017·Cancer Immunology Research

Abstract

We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non–small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival [PFS; objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared with patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation cohort (P = 0.0006). The presence of liver metastasis significantly increased the likelihood of progression (OR, 1.852; P < 0.0001). In a subset of biopsied patients (n = 62), liver metastasis was associated with reduced CD8+ T-cell density at the invasive tumor margin (liver metastasis+ group, n = 547 ± 164.8; liver metastasis− group, n = 1,441 ± 250.7; P < 0.016). A reduced response rate and shortened PFS was also observed in NSCLC patients with liver metastasis [median PFS, 1.8 months; 95% confidence interval (CI), 1.4–2.0], compared with those without liver metastasis (n = 119, median PFS, 4.0 months; 95% CI, 2.1–5.1), P = 0.0094. Thus, liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases were associated with reduced marginal CD8+ T-cell infiltration, providing a potential mechanism for this outcome. Cancer Immunol Res; 5(5); 417–24. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0325

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 560

Metadata

Authors
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., Khurana, N., Nosrati, A., Krummel, M. F., Tucker, A., Sosa, E. V., Sanchez, P. J., Banayan, N., Osorio, J. C., Nguyen-Kim, D. L., Chang, J., Shintaku, I. P., Boasberg, P. D., Taylor, E. J., Munster, P. N., Algazi, A. P., Chmielowski, B., Dummer, R., Grogan, T. R., Elashoff, D., Hwang, J., Goldinger, S. M., Garon, E. B., Pierce, R. H., & Daud, A.
Venue
Cancer Immunology Research
Published
2017-05-01
Volume
5
Issue
5
Pages
417-424
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2607272476
Cited by
560
References
42
FWCI
16.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. https://app.cochat.ai/papers/10.1158/2326-6066.cir-16-0325
The paper
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., Khurana, N., Nosrati, A., Krummel, M. F., Tucker, A., Sosa, E. V., Sanchez, P. J., Banayan, N., Osorio, J. C., Nguyen-Kim, D. L., . . . Daud, A. (2017). Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-16-0325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.